The International Consortium for Prostate Cancer Genetics (ICPCG) received a grant for its whole exome sequencing project from the National Cancer Institute (NCI) through 2016. The ICPCG members are conducting whole exome sequencing studies and a genome-wide association study of 2,000 familial prostate cancer cases and matched controls to identify other prostate cancer-associated genetic variants. The genetic variants they find in the custom genotyping arrays could be used in Dr. Catalona’s SPORE grant proposal, which seeks to discover genetic variants associated with the aggressive types of prostate cancer that lead to the failure of active surveillance.
The ICPCG is a collaborative group conducting research on familial prostate cancer. The researchers in this group share a common interest in genetic susceptibility for prostate cancer. The ICPCG consists of 18 independent groups from more than 20 institutions in North America, Europe and Australia, all of whom have major individual research efforts and extensive collections of data on prostate cancer families. The group was formed in 1996 to provide a mechanism for performing large-scale pooled analyses. Dr. Catalona is the Principal Investigator of the Northwestern University site of the ICPCG.